Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 527 Published: April 29, 2022 Report Code: GMDGDHC22139IDB

B-Cell Hodgkin Lymphoma Pipeline market research report provides comprehensive information on the therapeutics under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) and features dormant and discontinued projects.

Key Targets in the B-Cell Hodgkin Lymphoma Pipeline Market

The key targets in the B-Cell Hodgkin Lymphoma Pipeline market are Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8, Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, Histone Deacetylase 1, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform, Histone Deacetylase, Histone Deacetylase 2, and Cells Expressing B Lymphocyte Antigen CD19. Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8 has the highest number of pipeline products.

B-Cell Hodgkin Lymphoma Pipeline Market, by Targets

B-Cell Hodgkin Lymphoma Pipeline Market, by Targets

For more target insights, download a free report sample

Types of MoA in the B-Cell Hodgkin Lymphoma Pipeline Market

The key mechanisms of action in the B-Cell Hodgkin Lymphoma Pipeline market are Cytotoxic To Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8, Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Histone Deacetylase 1 Inhibitor, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform Inhibitor, Cytotoxic T Lymphocyte Protein 4 Antagonist, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, Histone Deacetylase 3 Inhibitor, Leukocyte Surface Antigen CD47 Inhibitor, and Hepatitis A Virus Cellular Receptor 2 Inhibitor. Cytotoxic To Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8 has the maximum number of pipeline products.

B-Cell Hodgkin Lymphoma Pipeline Market, by MoA

B-Cell Hodgkin Lymphoma Pipeline Market, by MoA

For more MoA insights, download a free report sample

Types of RoA in the B-Cell Hodgkin Lymphoma Pipeline Market

The types of key RoA in the B-Cell Hodgkin Lymphoma Pipeline market are intravenous, oral, parenteral, subcutaneous, intratumor, intravenous drip, intralesional, intraperitoneal, and topical. In the B-Cell Hodgkin Lymphoma Pipeline market, intravenous has the highest number of pipeline products.

B-Cell Hodgkin Lymphoma Pipeline Market, by RoA

B-Cell Hodgkin Lymphoma Pipeline Market, by RoA

For more RoA insights, download a free report sample

Key Molecule Types in the B-Cell Hodgkin Lymphoma Pipeline Market

The key molecule types in the B-Cell Hodgkin Lymphoma Pipeline market are small molecule, monoclonal antibody, gene-modified cell therapy, monoclonal antibody conjugated, cell therapy, fusion protein, antibody, antisense RNAi oligonucleotide, gene therapy, and oligonucleotide. Small molecule has the highest number of pipeline products.

B-Cell Hodgkin Lymphoma Pipeline Market, by Molecule Type

B-Cell Hodgkin Lymphoma Pipeline Market, by Molecule Type

For more molecule type insights, download a free report sample

Key Companies in the B-Cell Hodgkin Lymphoma Pipeline Market

The key companies in the B-Cell Hodgkin Lymphoma Pipeline market are Bristol-Myers Squibb Co, AstraZeneca Plc, Merck & Co Inc, Seagen Inc, Gilead Sciences Inc, Hebei Senlang Biotechnology Co Ltd, Incyte Corp, and Pfizer Inc. Bristol-Myers Squibb Co has the majority number of pipeline products.

B-Cell Hodgkin Lymphoma Pipeline Market, by Companies

B-Cell Hodgkin Lymphoma Pipeline Market, by Companies

To know more about companies, download a free report sample

Market report overview

Key targets Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8, Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, Histone Deacetylase 1, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform, Histone Deacetylase, Histone Deacetylase 2, and Cells Expressing B Lymphocyte Antigen CD19
Key MoA Cytotoxic To Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8, Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Histone Deacetylase 1 Inhibitor, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform Inhibitor, Cytotoxic T Lymphocyte Protein 4 Antagonist, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, Histone Deacetylase 3 Inhibitor, Leukocyte Surface Antigen CD47 Inhibitor, and Hepatitis A Virus Cellular Receptor 2 Inhibitor
Key RoA Intravenous, Oral, Parenteral, Subcutaneous, Intratumor, Intravenous Drip, Intralesional, Intraperitoneal, and Topical
Key molecule types Small Molecule, Monoclonal Antibody, Gene-Modified Cell Therapy, Monoclonal Antibody Conjugated, Cell Therapy, Fusion Protein, Antibody, Antisense RNAi Oligonucleotide, Gene Therapy, and Oligonucleotide
Key companies Bristol-Myers Squibb Co, AstraZeneca Plc, Merck & Co Inc, Seagen Inc, Gilead Sciences Inc, Hebei Senlang Biotechnology Co Ltd, Incyte Corp, and Pfizer Inc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Hodgkin Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hodgkin Lymphoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hodgkin Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hodgkin Lymphoma (Oncology)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hodgkin Lymphoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hodgkin Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Players

  • A. Menarini Industrie Farmaceutiche Riunite Srl

    AbbVie Inc

    ADC Therapeutics SA

    Adlai Nortye Biopharma Co Ltd

    Affimed GmbH

    Alfasigma SpA

    Angiocrine Bioscience Inc

    Apollomics Inc

    Astellas Pharma Inc

    AstraZeneca Plc

    Aurigene Discovery Technologies Ltd

    Avipep Pty Ltd

    Bayer AG

    BeiGene Ltd

    Bio-Path Holdings Inc

    Biohaven Pharmaceutical Holding Company Ltd

    Bristol-Myers Squibb Co

    Carrick Therapeutics Ltd

    Catalent Inc

    Cellectar Biosciences Inc

    Cellectis SA

    Celleron Therapeutics Ltd

    Cellestia Biotech AG

    Cellular Biomedicine Group Inc

    Celularity Inc

    Checkmate Pharmaceuticals Inc

    Checkpoint Therapeutics Inc

    Chimeric Therapeutics Ltd

    CSL Ltd

    CStone Pharmaceuticals Co Ltd

    Curis Inc

    Daiichi Sankyo Co Ltd

    Dyadic International Inc

    Eutilex Co Ltd

    Faron Pharmaceuticals Oy

    Genentech USA Inc

    Gibson Oncology LLC

    Gilead Sciences Inc

    Glenmark Pharmaceuticals Ltd

    Guangzhou Sinogen Pharmaceutical Co Ltd

    Hangzhou Sumgen Biotech Co Ltd

    Harbin Gloria Pharmaceuticals Co Ltd

    Hebei Senlang Biotechnology Co Ltd

    Helocyte Biosciences Inc

    HRAIN Biotechnology Co Ltd

    Hutchison MediPharma Ltd

    Immune Cell Inc

    ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd

    Incyte Corp

    Inhibrx Inc

    Innovent Biologics Inc

    Intellia Therapeutics Inc

    Kymera Therapeutics Inc

    LegoChem Biosciences Inc

    Luye Pharma Group Ltd

    Magenta Therapeutics Inc

    Marker Therapeutics Inc

    MediSix Therapeutics Pte Ltd

    Merck & Co Inc

    Merck KGaA

    Millennium Pharmaceuticals Inc

    Miltenyi Biotec BV & Co KG

    Mirati Therapeutics Inc

    NewBio Therapeutics Inc

    Northlake International LLC

    OncoTartis Inc

    Ono Pharmaceutical Co Ltd

    Pfizer Inc

    PlantForm Corp

    Protheragen Inc

    Rafael Pharmaceuticals Inc

    RAPT Therapeutics Inc

    Regeneron Pharmaceuticals Inc

    Rhizen Pharmaceuticals SA

    Rich Pharmaceuticals Inc

    Rizen (Suzhou) Biosciences Co Ltd

    Sanofi

    Seagen Inc

    Shanghai First Song Therapeutics Co Ltd

    Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

    Shanghai Junshi Bioscience Co Ltd

    Shanghai Pharmaceutical Group Co Ltd

    Shanghai Pharmaceuticals Holding Co Ltd

    Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd

    Shanghai YaKe Biotechnology Co Ltd

    Shattuck Labs Inc

    Shenzhen Chipscreen Biosciences Co Ltd

    Sichuan Kelun Pharmaceutical Co Ltd

    SpecificiT Pharma Inc

    Suzhou Everhealth Biomedical Co Ltd

    Syndax Pharmaceuticals Inc

    Tacitus Therapeutics Inc

    Takeda Pharmaceutical Co Ltd

    Tessa Therapeutics Ltd

    Tevogen Bio Inc

    Tubulis GmbH

    Tyme Inc

    Vincerx Pharma Inc

    Viracta Therapeutics Inc

    Waterstone Hanxbio Pty Ltd

    Wuhan Bio-Raid Biotechnology Co Ltd

    Xencor Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Overview

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Companies Involved in Therapeutics Development

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Drug Profiles

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Dormant Projects

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Discontinued Products

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Product Development Milestones

Featured News & Press Releases

Apr 11, 2022: Glenmark Specialty S.A. receives approval for conducting phase 1 clinical trial of its novel molecule GRC 54276 in patients with advanced solid tumors and Hodgkin’s lymphoma

Apr 10, 2022: Affimed presents updated clinical data from phase 1/2 study of AFM13 precomplexed with cord blood-derived NK cells at AACR Annual Meeting

Dec 14, 2021: Tessa Therapeutics announces positive data from phase 2 trial of autologous CD30-CAR-T therapy (TT11) in relapsed or refractory classical hodgkin lymphoma at 2021 ASH Annual Meeting

Dec 12, 2021: Seagen announces preliminary results from phase 2 clinical trial of ADCETRIS (brentuximab vedotin) in novel combination of agents for patients with advanced stage classical hodgkin lymphoma

Dec 09, 2021: Affimed to host virtual investor call today to discuss treatment of CD30-positive lymphoma patients with cord blood-derived natural killer cells pre-complexed with innate cell engager AFM13

Dec 02, 2021: BeiGene announces inclusion in the China National Reimbursement Drug List (NRDL) of Tislelizumab in three new indications

Dec 02, 2021: Innovent and Lilly announce successful expansion of Sintilimab in China National Reimbursement Drug List to include three additional first-line indications

Nov 04, 2021: Seagen to highlight multiple ADCETRIS (brentuximab vedotin) data presentations at the upcoming 2021 American Society of Hematology (ASH) Annual Meeting

Nov 03, 2021: Tessa Therapeutics announces presentation of autologous cell therapy data at 2021 ASH Annual Meeting

Sep 27, 2021: ONO receives approval of Opdivo (nivolumab) for dosage and administration for treatment of Pediatric Patients with Recurrent or Refractory Classical Hodgkin Lymphoma in Japan

Aug 30, 2021: Ligand’s partner Gloria Biosciences receives approval in China for zimberelimab for the treatment of recurrent or refractory classical Hodgkin’s lymphoma

Jun 22, 2021: ADC Therapeutics announces encouraging interim results from pivotal phase 2 clinical trial of Camidanlumab Tesirine (Cami) presented at the 16th Annual International Conference on Malignant Lymphoma

Jun 09, 2021: ADC Therapeutics announces presentation on Camidanlumab at the 16th Annual International Conference on Malignant Lymphoma

May 26, 2021: ADC Therapeutics announces online publication of Camidanlumab Tesirine phase 1 results in The Lancet Haematology

May 14, 2021: Tessa Therapeutics announces positive, topline data from ongoing phase 1 trial of allogeneic, “Off-the-Shelf” cell therapy, in patients with relapsed or refractory CD30-positive lymphoma

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by AbbVie Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by ADC Therapeutics SA, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Adlai Nortye Biopharma Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Affimed GmbH, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Alfasigma SpA, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Angiocrine Bioscience Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Apollomics Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Astellas Pharma Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by AstraZeneca Plc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Aurigene Discovery Technologies Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Avipep Pty Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Bayer AG, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by BeiGene Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Bio-Path Holdings Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Biohaven Pharmaceutical Holding Company Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Bristol-Myers Squibb Co, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Carrick Therapeutics Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Catalent Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Cellectar Biosciences Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Cellectis SA, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Celleron Therapeutics Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Cellestia Biotech AG, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Cellular Biomedicine Group Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Celularity Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Checkmate Pharmaceuticals Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Checkpoint Therapeutics Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Chimeric Therapeutics Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by CSL Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by CStone Pharmaceuticals Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Curis Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Daiichi Sankyo Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Dyadic International Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Eutilex Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Faron Pharmaceuticals Oy, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Genentech USA Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Gibson Oncology LLC, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Gilead Sciences Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Glenmark Pharmaceuticals Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Guangzhou Sinogen Pharmaceutical Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Hangzhou Sumgen Biotech Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Harbin Gloria Pharmaceuticals Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Hebei Senlang Biotechnology Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Helocyte Biosciences Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by HRAIN Biotechnology Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Hutchison MediPharma Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Immune Cell Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Incyte Corp, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Inhibrx Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Innovent Biologics Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Intellia Therapeutics Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Kymera Therapeutics Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by LegoChem Biosciences Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Luye Pharma Group Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Magenta Therapeutics Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Marker Therapeutics Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by MediSix Therapeutics Pte Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Merck & Co Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Merck KGaA, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Millennium Pharmaceuticals Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Miltenyi Biotec BV & Co KG, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Mirati Therapeutics Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by NewBio Therapeutics Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Northlake International LLC, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by OncoTartis Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Ono Pharmaceutical Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Pfizer Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by PlantForm Corp, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Protheragen Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Rafael Pharmaceuticals Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by RAPT Therapeutics Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Regeneron Pharmaceuticals Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Rhizen Pharmaceuticals SA, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Rich Pharmaceuticals Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Rizen (Suzhou) Biosciences Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Sanofi, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Seagen Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shanghai First Song Therapeutics Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shanghai Pharmaceutical Group Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shanghai Pharmaceuticals Holding Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shanghai YaKe Biotechnology Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shattuck Labs Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Sichuan Kelun Pharmaceutical Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by SpecificiT Pharma Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Suzhou Everhealth Biomedical Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Syndax Pharmaceuticals Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Tacitus Therapeutics Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Takeda Pharmaceutical Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Tessa Therapeutics Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Tevogen Bio Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Tubulis GmbH, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Tyme Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Vincerx Pharma Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Viracta Therapeutics Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Waterstone Hanxbio Pty Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Wuhan Bio-Raid Biotechnology Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Xencor Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Dormant Projects, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently Asked Questions

$2500

Can be used by individual purchaser only

$7500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.